OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Stock
Fundamentals
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 1 articles
published over the past 14 days
About OnKure Therapeutics, Inc. Class A Common Stock
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director | 1959 |
| Mr. Jason A. Leverone CPA | Chief Financial Officer | 1974 |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 1973 |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary | — |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery | — |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology | — |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry | — |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
2 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.6 | -14.3 | -9.7 | -18.5 |




